Tricida, Inc., a South San Francisco, CA-based Phase 3 stage biopharmaceutical company focused on the discovery and development of non-absorbed oral drug therapies, closed a $57.5m Series D financing.
Wellington Management Company LLP, Venrock Healthcare Capital Partners and Cormorant Asset Management joined existing investors OrbiMed, Longitude Capital, Sibling Capital Ventures, Limulus Venture Partners and Vivo Capital in the round bringing the company’s total capital raised to-date to $153.3m.
The company intends to use the funds to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101, its investigational drug candidate for the treatment of chronic metabolic acidosis in patients with chronic kidney disease (CKD).
Led by Gerrit Klaerner, Ph.D., Chief Executive Officer, and Geoff Parker, Chief Financial Officer, Tricida is advancing TRC101, a new chemical entity being developed as an orally administered, counterion-free, insoluble, non-absorbed polymeric drug for the treatment of metabolic acidosis in patients with chronic kidney disease (CKD).
If successful, the TRCA-301 Phase 3 clinical trial will serve as the pivotal trial for the submission of a U.S. New Drug Application for TRC101 under the FDA’s accelerated approval pathway.